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Human selenium binding protein 1 (SELENBP1), which
binds covalently to selenium is a member of selenium-contain-
ing proteins. The SELENBP1 gene is located on chromosome
1q21-22 and it encodes a protein of 472 amino acids.1,2 SEL-
ENBP1 has been implicated to play a role in the toxification/
detoxification processes,3 cell-growth regulation,4 intra-Golgi
protein transport,5 and lipid metabolism.6 However, the detailed
functions of this protein are not known. SELENBP1 is expressed
in the epithelium of the stomach, colorectum, liver, lung, breast,
prostate, thyroid gland, and kidney.7,8 The decreased expression
of SELENBP1 has been reported in several carcinomas, includ-
ing lung adenocarcinoma,9 colorectal adenocarcinoma,7,10 prostate
adenocarcinoma,8 stomach adenocarcinoma,11 ovarian epithelial
carcinoma,12 and thyroid papillary carcinoma.13 The association
between the decreased expression of this protein and a poor prog-
nosis has been demonstrated for lung adenocarcinomas9 and
colorectal adenocarcinomas.7,10 Additionally, it has been report-
ed that the decreased expression of this protein is a late event in
colorectal carcinogenesis.7 Loss of heterozygosity and methyla-
tion of promoter CpG islands do not account for the suppres-
sion of this protein in lung adenocarcinomas and colorectal car-
cinomas.7,9,10
Gastric carcinoma is one of the leading causes of death world-
wide, despite of a marked decline of its incidence in the West.14
Especially in Korea, gastric carcinoma is the second leading cause
of death.15 It is widely accepted that gastric carcinogenesis is a
multistep process that progresses from chronic gastritis, atro-
phy, intestinal metaplasia to dysplasia/adenoma, and it finally
leads to gastric carcinoma, especially for the intestinal type of
gastric carcinoma.16 There are many molecular alterations involved
in the gastric adenoma-carcinoma sequence, including APC
mutation, p53 mutation and loss of heterozygosity, the reduced
expression of p27, and the increased expression of cyclin E.17 The
sequential changes of the SELENBP1 expression in gastric dys-
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Background : Human selenium binding protein 1 (SELENBP1) is a protein that binds seleni-
um as a cofactor. The decreased expression of SELENBP1 in several types of carcinomas
and its association with a poor prognosis have previously been reported on. In this study, we
evaluated the expression of SELENBP1 in low-grade and high-grade epithelial dysplasia/
adenomas and adenocarcinomas. Methods : We analyzed 45 cases of low-grade epithelial
dysplasia/adenomas, 42 cases of high-grade epithelial dysplasia/adenomas and 64 cases of
adenocarcinomas and all of them were obtained from endoscopic mucosal resection or endo-
scopic submucosal dissection. We analyzed all of them for their SELENBP1 expression by
immunohistochemistry. Eight triple-paired cases of gastric mucosa, adenoma and adenocar-
cinoma from the same patient were selected for RT-PCR analysis. Results : There was a
progressive decrease in the expression of SELENBP1 from the low-grade dysplasia/adeno-
mas (42/45, 93%) to the high-grade dysplasia/adenomas (29/42, 69%) and finally to the ade-
nocarcinomas (24/64, 37%), (p<0.001). The progressive decrease in the SELENBP1 expres-
sion was also evident in the eight paired cases that were analyzed by RT-PCR. Conclusions :
Our findings demonstrate that the SELENBP1 expression is suppressed in gastric epithelial
dysplasia/adenomas and adenocarcinomas. The suppression of SELENBP1 was significant-
ly more frequent and severer in the adenocarcinomas than that in the low-grade dysplasia/
adenomas, and this implies that the suppression of SELENBP1 is a late event in gastric car-
cinogenesis. 
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plasia/adenomas to early stage carcinomas can provide insights
into the carcinogenetic pathways and this can aid in the detec-
tion of molecular targets for making a proper diagnosis or select-
ing a specific treatment. In this study, we evaluated the changes
of the SELENBP1 expression in low-grade and high-grade epithe-
lial dysplasia/adenomas and adenocarcinomas by immunohisto-
chemistry, with a focus on the multistep carcinogenesis of intesti-
nal-type adenocarcinoma, on the formalin-fixed paraffin-embed-
ded specimens obtained from endoscopic mucosal resection or
endoscopic submucosal dissection. We also evaluated the changes
of the SELENBP1 mRNA expression by RT-PCR on the snap-
frozen tissues obtained from total or subtotal gastrectomy. 
MATERIALS AND METHODS
Case selection and histologic review
We reviewed three consecutive series of 45 low-grade epithe-
lial dysplasia/adenomas that were obtained between November
2006 and May 2007, 42 high-grade epithelial dysplasia/adeno-
mas that were obtained between December 2006 and March
2008, and 64 adenocarcinomas that were obtained between
September 2006 and March 2008, and all the specimens were
the products of endoscopic mucosal resection or endoscopic sub-
mucosal dissection. These specimens were obtained from the
archives of the Department of Pathology, Yonsei University,
Seoul, Korea. Authorization for the use of these tissues for research
purposes was obtained from the Institutional Review Board of
Yonsei University of College of Medicine. In this study, we adopt-
ed the WHO system which is a two-tired system of low-grade
and high-grade epithelial dysplasia/adenoma, for the classifica-
tion of the neoplastic precursor lesions. We used the definition
of carcinoma as invasion into the lamina propria or beyond, as
recommended by the WHO.17 For the selection of adenocarci-
nomas, in order to avoid confusion between high-grade dyspla-
sia, carcinoma in situ and intramucosal adenocarcinoma, we only
included those tumors that had invaded the muscularis mucosa
or submucosa. The cases containing concomitant low-grade and
high-grade dysplasia/adenoma or high-grade dysplasia/adeno-
ma and adenocarcinoma were grouped according to the worst
grade. All the specimens were routinely fixed in 10% buffered
formalin, serially sectioned and embedded in paraffin, cut at 3
μm thickness and then stained with hematoxylin-eosin. Each
lesion was independently reviewed by two pathologists (Hy Kim
and Ho Kim). The gross type, size and state of the non-neoplas-
tic mucosa were reevaluated. For the validation of the SELENBP1
expression at the RNA level, eight triple-paired cases of non-
neoplastic mucosa, dysplasia/adenoma and adenocarcinoma from
the same patient were selected and evaluated by RT-PCR analysis.
All the eight cases were snap-frozen samples that were obtained
immediately at the time of surgery. Of the eight cases, five cases
(case 2, 3, 6, 7, and 8) had separate low-grade epithelial dyspla-
sia/adenoma and the other three cases (case 1, 4, and 5) had low-
grade dysplasia/adenoma that bordered adenocarcinoma. The
carcinomatous components of case 6 and case 8 were the signet
ring cell type and the mucinous type, respectively. Each speci-
men was microdissected on a cryostat and then fractionated to
enrich the tumor cell population, which was ultimately com-
prised of greater than 70% tumor cells.
Immunohistochemistry
The representative 4 μm-thick sections were deparaffinized
and rehydrated through a graded series of xylene and alcohol solu-
tion. The endogenous peroxidase was blocked with 3% aqueous
hydrogen peroxide. The slides were pretreated in a microwave
oven for antigen retrieval. The sections were incubated with anti-
SELENBP1 antibody (mouse antihuman monoclonal antibody,
M061-3, clone 4D4, MBL, Nagoya, Japan) at a 1:500 dilution
for 1 h at room temperature and then overnight at 4℃. The
antibodies were detected using the avidin-biotin complex method
with diaminobenzidine as a chromogen. The slides were coun-
terstained with hematoxylin. In the cases containing concomi-
tant low-grade and/or high-grade dysplasia/adenoma and/or
adenocarcinoma, the expression of SELENBP1 was evaluated
only in the worst lesion. A semi-quantitative scale from 0 to
100% was used to grade the percentage of SELENBP1-stained
tumor cells. For Table 2, 3, the cases with more than 10% im-
munoreactive tumor cells were categorized as positive and the
cases with 10% or less than 10% immunoreactive tumor cells
were categorized as negative.
RT-PCR
Total RNA was extracted from 100-200 mg of the microdis-
sected frozen tissues with using a RNeasy Mini kit (Qiagen,
Valencia, CA, USA), according to the manufacturer’s instruc-
tions. First-strand cDNA was synthesized from 1 μg of the total
RNA with using random hexamer primers (Qiagen) and M-
MLV Reverse Transcriptase (Invitrogen, San Diego, CA, USA)
according to the manufacturer’s instructions. Twenty nanograms
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of cDNA from each sample was used in each reaction. The reac-
tion was performed with the primers for SELENBP1 and for β-
actin in a duplex reaction. The sequences of the forward and
reverse primers for SELENBP1 and β-actin were as follows:
forward primer for SELENBP1: 5′-CCCAGTCTCATCTCCT-
CTCG-3′, reverse primer for SELENBP1: 5′-GTCTCTCCCA-
TGTCCCCTTC-3′, forward primer for β-actin: 5′-TGCTAT-
CCCTGTACGCCTCT-3′, reverse primer for β-actin: 5′-GTA-
CTTGCGCTCAGGAGGAG-3′. The SELENBP1 primers were
designed to contain two sites of the exon-exon junction in the
PCR product, and β-actin primers were designed to contain an
exon-exon junction. β-actin was used as an internal control. After
the RT-PCR, 5 μL aliquots of the products were subjected to
2% agarose gel electrophoresis and then staining was done with
ethidium bromide.
Statistical analysis
The statistical analysis was performed using Pearson’s χ2 test
for Table 1, 2, and by one-way ANOVA for Fig. 2. The statisti-
cal calculations were performed with the SSPS version 13.0 for
Windows software (SPSS Inc, Chicago, IL, USA) and a p-value
<0.05 was considered statistically significant. 
RESULTS
The clinicopathologic characteristics of the gastric 
adenomas and the adenocarcinomas
The study group was composed of 45 cases of low-grade dys-
plasia/adenomas, 42 cases of high-grade dysplasia/adenomas and
64 cases of adenocarcinomas. There were no significant differ-
ences between these groups for the age distribution or the male-
female ratio. Although the difference was not statistically sig-
nificant, the adenocarcinomas were larger than the low-grade
and the high-grade dysplasia/adenomas (1.3±0.6 cm vs 0.8±
0.4 cm and 0.7±0.5 cm, respectively). The low-grade dyspla-
sia/adenomas were located in the carcia/body/fundus significant-
ly more often than were the high-grade dysplasia/adenomas and
adenocarcinomas (p=0.007), and the low-grade dysplasia/ade-
nomas were significantly more commonly associated with pro-
truded (I) or elevated lesions (IIa), when compared with the
high-grade dysplasia/adenomas and adenocarcinomas (p<0.001).
The state of the non-neoplastic mucosae was not different among
the three groups (Table 1).
The expression of SENENBP1 in the non-neoplastic
mucosae
SELENBP1 was found to be expressed in the gastric mucosa,
including the foveolar glands, the antral proper glands and the
fundic/body proper glands (Fig. 1A, B). It was also expressed in
the gastric mucosa with intestinal metaplasia and/or atrophy.
The other mesenchymal cells, including smooth muscle cells,
endothelial cells, inflammatory cells and fibrocytes/fiborblasts,
were completely negative for SELENBP1. 
Epithelial 
dysplasia, 
low-grade 
(n=45)
Epithelial
dysplasia,
high-grade
(n=42)
Adenocarci-
noma
(n=64)
Age (years, mean±SD) 63±8.6 65±10 63±10
Sex
Male 31 25 40
Female 13 17 24
Tumor size (cm, mean±SD) 0.8±0.4 0.7±0.5 1.3±0.6
Locationa
Cardia/fundus/body 21 (47%) 13 (31%) 13 (20%)
Antrum/pylorus 24 (53%) 29 (69%) 51 (80%)
Gross typeb
Protruded (I)/elevated (IIa) 22 (49%) 5 (12%) 7 (11%)
Flat (IIb)/depressed (IIc)/ 23 (51%) 37 (88%) 57 (89%)
ulcerated (III)
Non-neoplastic mucosa
Normal histology 1 1 2
Helicobacter gastritis 5 3 9
Intestinal metaplasia 29 27 35
Atrophy 10 11 18
a, Low-grade dysplasia vs high-grade dysplasia+adenocarcinoma,
p=0.007; b, Low-grade dysplasia vs high-grade dysplasia+adenocar-
cinoma, p<0.001.
Table 1. Clinicopathologic characteristics of the low-grade and
the high-grade epithelial dysplasia/adenomas and the adeno-
carcinomas
SELENBP1 expressiona
Negative
(≤10%)
Positive
(>10%)
Epithelial dysplasia, low-grade (n=45) 3 (7%) 42 (93%)
Epithelial dysplasia, high-grade (n=42) 13 (31%) 29 (69%)
Adenocarcinoma (n=64) 40 (63%) 24 (37%)
a, p<0.001 by Pearson’s χ2 test.
Low-grade vs high-grade dysplasia, p=0.005 by Fisher extract test.
High-grade dysplasia vs adenocarcinoma, p=0.001 by Pearson’s χ2 test.
Table 2. Progressive suppression of SELENBP1 expression in
the low-grade and the high-grade epithelial dysplasia/adeno-
mas and the adenocarcinomas
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The expression of SENENBP1 in the low-grade and the
high-grade dysplasia/adenomas, and the adenocarcinoma
The expression of SELENBP1 progressively decreased from
the low-grade and the high-grade dysplasia/adenomas to the
adenocarcinomas. The expression of SELENBP1 was markedly
suppressed in the adenocarcinomas as compared with the non-
neoplastic mucosae (Fig. 1C-F). SELENBP1 was expressed in
the surrounding mucosa in all the cases. In contrast, 3 of the 45
cases of low-grade dysplasia/adenomas, 13 of the 42 cases of
high-grade dysplasia/adenomas and 40 of the 64 cases of ade-
nocarcinomas showed a marked suppression of SELENBP1. The
high-grade dysplasia/adenomas revealed a statistically signifi-
cant loss of the SELENBP1 expression when compared to the
low-grade dysplasia/adenomas (p=0.005). The adenocarcinomas
revealed a significant loss of the SELENBP1 expression rather
than the high-grade dysplasia/adenoma (p<0.001), (Table 2).
A B C
D E F
Fig. 1. Immunohistochemical staining for SELENBP1 shows a SELENBP1 expression in a non-neoplastic gastric mucosa of the fundus/body
(A) and the antrum (B). The expression of SELENBP1 is slightly decreased in a low-grade epithelial dysplasia/adenoma (C), further dec-
reased in a high-grade dysplasia/adenoma (D) and markedly decreased in adenocarcinomas (E, F).
SELENBP1 expression
Negative
(≤10%)
Positive
(>10%)
Histologic type
Tubular adenocarcinomaa (n=61)
Well differentiated 26 18
Moderately differentiated 9 5
Poorly differentiated 2 1
Signet ring cell carcinoma (n=3) 3 0
Invasion depthb
Muscularis mucosa (n=25) 13 12
Submucosa (n=39) 23 16
a, p>0.05 by Pearson’s χ2 test; b, p>0.05 by Pearson’s χ2 test.
Table 3. Comparison of the SENEBP1 expression according to
the histologic type, the differentiation, and the invasion depth in
the 64 adenocarcinomas 
Fig. 2. Progressive suppression of SELENBP1 in the low-grade
and the high-grade epithelial dysplasia/adenomas and the ade-
nocarcinomas is statistically significant. The box plot shows
median (thick solid line in the box), interquartile range from the
first quartile to the third (box), maximum (upper thin solid line)
and minimum (lower thin solid line).
Ex
pr
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sio
n %
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EN
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1
100
80
60
40
20
0
Low grade High grade Adenocarcinoma
dysplasia (n=45) dysplasia (n=42) (n=64)
p=0.012
p<0.001
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The percentage of the SELENBP1 expression among the three
groups was also significantly different (Fig. 2). Twenty (44%)
of the 45 cases of low-grade dysplasia/adenomas, 8 (19%) of the
42 cases of high-grade dysplasia/adenomas and 4 (6%) of the
64 cases of adenocarcinomas showed a focal, but intensive expres-
sion of SELENBP1. The SELENBP1 expression in the adeno-
carcinomas did not vary according to the differentiation and
the invasion depth (Table 3).
The SENENBP1 RNA expression in eight paired cases
of gastric adenomas and adenocarcinomas
The reduced expression of SELENBP1 was validated by RT-
PCR for the eight paired cases. Of the eight paired cases, five
cases (case 1, 2, 4, 7, and 8) showed a normal SELENBP1 expres-
sion in the adenomas and a severely suppressed expression in
the adenocarcinomas. Two cases (cases 6 and 3) showed a con-
comitant SELENBP1 suppression in both the adenomas and
the adenocarcinomas. The remaining case (case 5) exhibited a
normal SELENBP1 expression in both the adenoma and the
carcinoma. Overall, two dysplasia/adenomas (25%) and seven
carcinomas (87.5%) showed a decreased SELENBP1 expression
(Fig. 3). These RT-PCR findings support the immunohisto-
chemical findings, and suggest that the suppression of SELE-
NBP1 occurs at the transcriptional level.
DISCUSSION
In this study, we demonstrate that the expression of SELENBP1
is progressively suppressed in gastric adenomas and adenocarci-
nomas. The suppression of SELENBP1 has been reported in
many cancers, including lung adenocarcinoma,9 colorectal ade-
nocarcinoma,7,10 prostate adenocarcinoma,8 stomach adenocarci-
noma,11 ovarian epithelial carcinoma,12 and thyroid papillary car-
cinoma.13 The suppression of SELENBP1 in gastric adenocarci-
noma suggests that SELENBP1 might be related to gastric car-
cinogenesis. One study has previously reported on the suppressed
expression of SELENBP1 in gastric adenocarcinoma on 10 car-
cinomas specimens with two-dimensional electrophoresis.11 How-
ever, there have not been any studies on the SELENBP1 expres-
sion in gastric adenomas. In this study, we demonstrated the
suppression of SELENBP1 in gastric adenomas and adenocarci-
nomas by immunohistochemistry, and we compared the level
of SELENBP1 expression between the groups. We found that
the SELENBP1 expression was decreased in some gastric ade-
nomas and we also found the progressive suppression of SELE-
NBP1 in gastric carcinomas. These findings indicate that expres-
sion of SELENBP1 is severely suppressed in gastric cancer.
SELENBP1 is a protein that binds selenium as a cofactor. Sele-
nium also becomes cotranslationally incorporated into a polypep-
tide chain as part of selenocysteine which is the 21st encoded
amino acid.18 The molecular mechanism for the suppression of
SELENBP1 in cancer cells is not presently clear. Promoter methy-
lation and gene deletion are not the mechanisms in lung ade-
nocarcinomas9 or colorectal adenocarcinomas.7 There have been
many reports that selenium supplementation can decrease the
risk of lung, colorectum and prostate cancers.19-22 The Nutri-
tional Prevention of Cancer trial, a 13-year, double-blind, ran-
domized, placebo-controlled clinical trial, was recently complet-
ed. The trial confirmed that selenium supplementation was asso-
ciated with marked reductions of the risk for the total cancer
incidence (relative risk [RR]=0.63) (for all sites except skin)
and of the risk for carcinomas of the prostate (RR=0.51) and
the colorectum (RR=0.46).22 The proposed mechanisms for the
protective role of selenium against cancer include inhibiting car-
cinogen-induced covalent DNA adduct formation, impeding
oxidative damage to DNA, lipids, and proteins, increasing apop-
β-actin
SELENBP1
Case 1 Case 2 Case 3 Case 4
N A C N A C N A C N A C
β-actin
SELENBP1
Case 5 Case 6 Case 7 Case 8
N A C N A C N A C N A C
Fig. 3. RT-PCR results of SELENBP1
in the paired gastric dysplasia/ade-
nomas and adenocarcinomas shows
a normal SELENBP1 expression in
adenomas and a decreased ex-
pression in adenocarcinomas (case
1, 2, 4, 7, and 8), a concomitant
decreased SELENBP1 expression
in both adenomas and adenocarci-
nomas (case 3 and 6), and a nor-
mal SELENBP1 expression in both
adenoma and carcinoma (case 5).
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tosis, inhibiting tumor cell growth, altering DNA, RNA, and
protein synthesis, and increasing p53 expression.23 Both our
results and previous studies, which have demonstrated a decreased
expression of SELENBP1 in several types of carcinomas, sug-
gest that the decreased expression of SELENBP1 may play a
role in the tumorigenesis of many types of carcinomas and that
the decreased expression of SELENBP1 may abrogate the chemo-
protective effects of selenium in tumorigenesis.
Although the percentage of the expression of SELENBP1 was
slightly decreased in the low-grade dysplasia/adenomas, the ex-
pression of SELENBP1 was relatively preserved in the low-grade
dysplasia/adenomas compared to that in the adenocarcinomas.
This finding was correlated with the findings from a previous
study that used a colorectal adenoma-carcinoma sequence model.7
This finding was also supported by the RT-PCR results. Among
the eight paired cases, five showed a markedly decreased mRNA
expression of SELENBP1 in the adenocarcinomas compared
with that in the non-neoplastic mucosae and the dysplasia/ade-
nomas. When the intensity of the RT-PCR product for the SE-
LENBP1 was adjusted by that for the β-actin, the dysplasia/
adenomas of cases 1, 2, and 4 showed a stronger expression of
SELENBP1 than that of the paired non-neoplastic mucosae.
This finding was also found on our immunohistochemical anal-
ysis. Although the percentage of the SELENBP1 expression was
decreased in the low-grade dysplasia/adenomas compared with
that of non-neoplastic mucosae, many low-grade dysplasia/ade-
nomas showed a focal, but intensive expression of SELENBP1.
In contrast, a generalized and severe suppression of SELENBP1
was noted in most carcinomas. Our immunohistochemistry and
RT-PCR results implicate that the suppression of SELENBP1
is a late event in gastric carcinogenesis. 
In conclusion, the SELENBP1 expression is markedly sup-
pressed in gastric adenocarcinomas and is a late event in gastric
carcinogenesis. Further study will be necessary to precisely deter-
mine the relationship between the SELENBP1 expression lev-
els and the clinicopathologic and/or molecular factors of gastric
carcinomas, including the histologic type according to Lauren,
the specific tumor type such as signet ring cell type or mucinous
type, the tumor stage, the prognosis, the presence of microsatel-
lite instability and several other genetic characteristics.
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